Skip to content
A Blog by Biocon

A Blog by Biocon

  • Home
  • About Us
  • Biocon Biologics
    • Biosimilars
    • Biocon Biologics @ IDF Congress 2019
      • Speaker Profiles
    • Itolizumab (ALZUMAb®) : Highly Promising Therapy for Cytokine Release Syndrome (CRS) in COVID-19
  • Healthcare
  • Innovation
  • Disease Epidemiology
  • Vodcast
  • Bioconites Corner
    • Work From Home
    • Campaigns
      • Har Ghar Tiranga
      • Mother’s Day
      • Lupus Day
  • Policy
  • Comments Policy
  • Contact

'BioConversations'

PM Narendra Modi recognizes Biocon and other Corporates for Contribution towards the Yellow Line Metro

PM Narendra Modi recognizes Biocon and other Corporates for Contribution towards the Yellow Line Metro

Biocon Q1FY26 Earnings is well-positioned for contined momentum and sustained growth

Biocon Q1FY26 Earnings is well-positioned for contined momentum and sustained growth

In Conversation with Dr. Praveen Raj for IDF, Thailand

In Conversation with Dr. Praveen Raj for IDF, Thailand

September 19, 2016September 20, 2016 Biocon Innovation

Personalized Medicine – Myth or Reality?

By Sreesha Srinivasa, PhD Associate Vice President, Research and Development, Biocon Research Limited.

September 1, 2016September 22, 2016 Biocon Innovation

Antibodies as Drugs

By Narendra Chirmule, PhD Senior VP & Head of Research and Development, Biocon Research Limited.

August 2, 2016September 1, 2016 Biocon Innovation

Can India Create the Next Apple or Google?

By Kiran Mazumdar Shaw Chairman & Managing Director, Biocon Limited.

August 1, 2016October 14, 2016 Biocon Biosimilars

Access and Affordability: Impact of Biosimilars

Part 1 – Biosimilars can provide cost-effective, high quality alternatives to expensive reference biologics, thus improving access and expanding the patient base.

August 1, 2016September 6, 2016 Biocon Innovation

Anemia – Sickle Cell Disease

By Narendra Chirmule, PhD Senior Vice President & Head, Research and Development, Biocon Research Limited.

July 11, 2016September 1, 2016 Biocon Policy

Why It’s Imperative To Look At The Impact Of Tax SOPs

By Kiran Mazumdar Shaw Chairman & Managing Director, Biocon Limited.

July 11, 2016September 1, 2016 Biocon Healthcare

The Global Right to Healthcare

By Kiran Mazumdar Shaw Chairman & Managing Director, Biocon Limited.

July 11, 2016September 1, 2016 Biocon Policy

Innovation, Not Price Control is the Answer to Affordable Bt Cotton Technology

By Kiran Mazumdar Shaw Chairman & Managing Director, Biocon Limited.

July 8, 2016August 8, 2016 Biocon Disease Epidemiology

Chronic Pain

Pain Management is a challenge to healthcare providers since the existing therapies have various associated cardiovascular and gastrointestinal side-effects.

Posts navigation

Newer posts
Biocon Employees come together to sing our National Anthem to mark 75th Independence Day.

Itolizumab: Highly Promising Therapy for Cytokine Release Syndrome (CRS) in COVID-19

DCGI Approval for emergency use of Itolizumab in treatment of Covid-19

Follow Biocon Biologics

BBL-X
BBL-Li
BBL-fb
BBL-Inst

Follow Biocon

Search

Biocon Limited

20th KM, Hosur Road,
Electronic City,
Bangalore, India - 560 100
Email: contact.us@biocon.com
+91 80 2808 2808 / 91 80 4014 4014

Archives

DISCLAIMER

Please read our Disclaimer and Comments Policy before engaging on our blog!

Create a website or blog at WordPress.com
  • Subscribe Subscribed
    • A Blog by Biocon
    • Join 116 other subscribers
    • Already have a WordPress.com account? Log in now.
    • A Blog by Biocon
    • Subscribe Subscribed
    • Sign up
    • Log in
    • Report this content
    • View site in Reader
    • Manage subscriptions
    • Collapse this bar
 

Loading Comments...